Therapeutic targeting in the silent era: advances in non-viral siRNA delivery

dc.contributor.authorGuo, Jianfeng
dc.contributor.authorFisher, Karen A.
dc.contributor.authorDarcy, Raphael
dc.contributor.authorCryan, John F.
dc.contributor.authorO'Driscoll, Caitríona M.
dc.contributor.funderScience Foundation Irelanden
dc.contributor.funderIrish Research Council for Science Engineering and Technologyen
dc.date.accessioned2013-01-29T10:11:16Z
dc.date.available2013-01-29T10:11:16Z
dc.date.copyright2010
dc.date.issued2010-04
dc.date.updated2013-01-17T10:53:32Z
dc.description.abstractGene silencing using RNA-interference, first described in mammalian systems almost a decade ago, is revolutionizing therapeutic target validation efforts both in vitro and in vivo. Moreover, the potential for using short interfering RNA (siRNA) as a therapy in its own right is also progressing at a significant pace. However, the widespread use of such approaches is contingent on having appropriate systems to achieve clinically appropriate, safe, and efficient delivery of siRNA. There are many physicochemical and biological barriers to such delivery, and a growing emphasis on the design and characterisation of non-viral technologies that will overcome these barriers and expedite targeted delivery. This review discusses the considerations and challenges associated with use of siRNA-based therapeutics, including stability and off-target effects. Speculation is made on the properties of an ideal delivery system and the non-viral delivery approaches used to date, both in vitro and in vivo, are classified and discussed. Moreover, the ability of cyclodextrin-based delivery vectors to fulfil many of the criteria of an ideal delivery construct is also elaborated.en
dc.description.sponsorshipScience Foundation Ireland (Strategic Research Cluster (Irish Drug Delivery Network); Science Foundation Ireland (Centre for Science Engineering & Technology); Science Foundation Ireland (Research Frontiers Programmes); Irish Research Council for Science Engineering and Technology (Embark initiative)en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationGUO, J., FISHER, K. A., DARCY, R., CRYAN, J. F. & O'DRISCOLL, C. 2010. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Molecular BioSystems, 6, 1143-1161. doi: 10.1039/c001050men
dc.identifier.doi10.1039/c001050m
dc.identifier.endpage1161en
dc.identifier.issn1742-206X
dc.identifier.journaltitleMolecular Biosystemsen
dc.identifier.startpage1143en
dc.identifier.urihttps://hdl.handle.net/10468/933
dc.identifier.volume6en
dc.language.isoenen
dc.publisherRoyal Society of Chemistryen
dc.relation.urihttp://pubs.rsc.org/en/content/articlelanding/2010/mb/c001050m
dc.rights© 2010 Royal Society of Chemistryen
dc.subjectsiRNA-based therapeuticsen
dc.subjectNon-viral technologiesen
dc.subjectCyclodextrinen
dc.subject.lcshGene silencingen
dc.subject.lcshDrug delivery systemsen
dc.titleTherapeutic targeting in the silent era: advances in non-viral siRNA deliveryen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Guo_et_al_Molecular_Biosystems.pdf
Size:
1.26 MB
Format:
Adobe Portable Document Format
Description:
Accepted Version
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description: